Key result
Mycosis fungoides was associated with significantly elevated serum periostin levels compared to healthy controls (median 12.60 vs 5.05 ng/mL, p<0.0001), demonstrating moderate diagnostic discrimination.
Why the study?
Serum biomarkers with diagnostic and staging relevance in mycosis fungoides remain limited.
Does serum periostin level distinguish patients with mycosis fungoides from healthy controls and correlate with clinical subtype and disease stage?
Case-Control (n=80)
No
Does serum periostin level distinguish patients with mycosis fungoides from healthy controls and correlate with clinical subtype and disease stage?
Absolute Event Rate: 12.6% vs 5.05%
p-value: p=<0.0001
Serum periostin is elevated in mycosis fungoides and varies by clinical subtype and stage, suggesting its potential as a supportive biomarker for microenvironmental activity.
May support periostin as MF biomarker candidate; leaves open diagnostic utility pending prospective validation.
Serum biomarkers with diagnostic and staging relevance in mycosis fungoides (MF) remain limited. In this prospective case-control study, we evaluated serum periostin levels in 40 patients with MF and 40 matched healthy controls, and assessed their associations with clinical subtype and disease stage. Serum periostin was measured by enzyme-linked immunosorbent assay (ELISA), and comparisons were performed using non-parametric tests. Serum periostin levels were significantly higher in patients with MF than in controls (p<0.0001). Receiver operating characteristic (ROC) analysis demonstrated moderate discrimination for MF, with an area under the curve (AUC) of 0.77 (95% confidence interval [CI], 0.67-0.88); the optimal cut-off was 7.50 ng/mL, yielding 74.36% sensitivity and 70.00% specificity. Periostin levels also differed significantly across clinical subtypes (Kruskal-Wallis, p<0.0001), with higher levels in patch and plaque disease than in tumor-stage disease. In addition, serum periostin was significantly higher in early-stage MF (IA-IIA) than in advanced-stage disease (IIB and above) (p=0.035). These findings support serum periostin as a supportive biomarker reflecting clinical subtype and stage in MF, warranting further validation.
No takes yet. Share an insight, caveat, or question.
Çetin et al. (2026) conducted a case-control in Mycosis fungoides (n=80). Mycosis fungoides vs. Healthy controls was evaluated on Serum periostin levels (ng/mL) (p=<0.0001). Mycosis fungoides was associated with significantly elevated serum periostin levels compared to healthy controls (median 12.60 vs 5.05 ng/mL, p<0.0001), demonstrating moderate diagnostic discrimination.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: